title: Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD.
authors.forename: Thomas
authors.initials: T
authors.lastname: Fleming
authors.forename: Steven E
authors.initials: SE
authors.lastname: Nissen
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Borer
authors.forename: Paul W
authors.initials: PW
authors.lastname: Armstrong
mesh_terms: D000083:Acetanilides; D000787:Angina Pectoris / Q000188:drug therapy*; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004348:Drug Labeling; D006801:Humans; D008396:Maryland; D009203:Myocardial Infarction / Q000517:prevention & control*; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069458:Ranolazine
chemical_list: D000083:Acetanilides; D003692:Delayed-Action Preparations; D010879:Piperazines; D000069458:Ranolazine; D001241:Aspirin